Ultragenyx Pharmaceutical
Stock Forecast, Prediction & Price Target
Ultragenyx Pharmaceutical (RARE) stock Price Target by analysts
$90
Potential upside: 201.00%
Ultragenyx Pharmaceutical price prediction
What is Ultragenyx Pharmaceutical stock analysts` prediction?
Ultragenyx Pharmaceutical stock forecast: Based on 2 Wall Street analysts` predicted price targets for Ultragenyx Pharmaceutical in the last 3 months, the avarage price target is $90, with a high forecast of $NaN. The average price target represents a 201.00% change from the last price of $29.9.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Ultragenyx Pharmaceutical stock Price Target by analysts
Full breakdown of analysts given Ultragenyx Pharmaceutical price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Ed Arce H.C. Wainwright | 0% 0/1 | 10 months ago | $95 217.72% upside | $51.2 | StreetInsider | Previous targets (0) |
Joseph Schwartz Leerink Partners | 0% 0/1 | 10 months ago | $85 184.28% upside | $51.2 | StreetInsider | Previous targets (0) |
Salveen Richter Goldman Sachs | 0% 0/1 | over 1 year ago | $67 124.08% upside | $41.45 | StreetInsider | Previous targets (0) |
Whitney Ijem Canaccord Genuity | 0% 0/1 | over 1 year ago | $111 271.23% upside | $38.65 | StreetInsider | Previous targets (0) |
Joel Beatty Robert W. Baird | 0% 0/1 | over 1 year ago | $72 140.80% upside | $38.65 | StreetInsider | Previous targets (0) |
Dae Gon Ha Stifel Nicolaus | 0% 0/2 | over 1 year ago | $127 324.74% upside | $38.65 | StreetInsider | Previous targets (1) |
Christopher Raymond Raymond James | 0% 0/2 | over 1 year ago | $135 351.50% upside | $38.65 | StreetInsider | Previous targets (1) |
Christopher Raymond Raymond James | 0% 0/2 | over 1 year ago | $130 334.78% upside | $42.87 | StreetInsider | Previous targets (1) |
Dae Gon Ha Stifel Nicolaus | 0% 0/2 | over 1 year ago | $124 314.71% upside | $42.87 | StreetInsider | Previous targets (1) |
Unknown Morgan Stanley | N/A | over 2 years ago | $95 217.72% upside | $47.03 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | over 2 years ago | $82 174.24% upside | $46.33 | Benzinga | N/A |
Christopher Raymond Piper Sandler | 0% 0/3 | about 3 years ago | $130 334.78% upside | $51.88 | TheFly | Previous targets (2) |
Unknown Stifel Nicolaus | N/A | about 3 years ago | $142 374.91% upside | $59.66 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 3 years ago | $101 237.79% upside | $47.22 | Benzinga | N/A |
Christopher Raymond Piper Sandler | 0% 0/3 | over 3 years ago | $135 351.50% upside | $47.7 | TheFly | Previous targets (2) |
Unknown Morgan Stanley | N/A | over 3 years ago | $109 264.54% upside | $58.59 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 3 years ago | $115 284.61% upside | $66.43 | Benzinga | N/A |
Yaron Werber Cowen & Co. | 0% 0/1 | over 3 years ago | $124 314.71% upside | $73.1 | StreetInsider | Previous targets (0) |
Yigal Nochomovitz Citigroup | 0% 0/1 | almost 4 years ago | $150 401.67% upside | $86 | TheFly | Previous targets (0) |
Laura Chico Wedbush | 0% 0/1 | almost 4 years ago | $92 207.69% upside | $86 | StreetInsider | Previous targets (0) |
Christopher Raymond Piper Sandler | 0% 0/3 | almost 4 years ago | $170 468.56% upside | $88.66 | TheFly | Previous targets (2) |
Esther Rajavelu UBS | 100% 1/1 | about 4 years ago | $73 144.14% upside | $77.92 | TheFly | Previous targets (0) |
Gena Wang Barclays | 0% 0/1 | about 4 years ago | $141 371.57% upside | $83.77 | TheFly | Previous targets (0) |
Ultragenyx Pharmaceutical Financial Estimates
Ultragenyx Pharmaceutical Revenue Estimates
Ultragenyx Pharmaceutical EBITDA Estimates
Ultragenyx Pharmaceutical Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $351.40M N/A | $363.32M 3.39% | $434.24M 19.51% | Avg: $618.04M Low: $561.20M High: $673.98M avg. 42.32% | Avg: $847.40M Low: $789.15M High: $926.97M avg. 37.11% | Avg: $1.16B Low: $1.08B High: $1.27B avg. 37.74% | Avg: $1.79B Low: $1.66B High: $1.95B avg. 53.36% |
Net Income
% change YoY
| $-454.02M N/A | $-707.42M -55.81% | $-606.63M 14.24% | Avg: $-491.86M Low: $-495.68M High: $-285.35M avg. 18.92% | Avg: $-335.72M Low: $-444.20M High: $-47.06M avg. 31.74% | Avg: $-63.33M Low: $-71.07M High: $-57.67M avg. 81.13% | Avg: $233.40M Low: $212.55M High: $261.89M avg. 468.50% |
EBITDA
% change YoY
| $-381.49M N/A | $-639.41M -67.60% | $-516.45M 19.22% | Avg: $-618.04M Low: $-673.98M High: $-561.20M avg. -19.67% | Avg: $-847.40M Low: $-926.97M High: $-789.15M avg. -37.11% | Avg: $-1.16B Low: $-1.27B High: $-1.08B avg. -37.74% | Avg: $-1.79B Low: $-1.95B High: $-1.66B avg. -53.36% |
EPS
% change YoY
| -$6.7 N/A | -$10.12 -51.04% | -$8.25 18.47% | Avg: -$5.4 Low: -$6.74 High: -$3.88 avg. 34.50% | Avg: -$3.63 Low: -$6.04 High: -$0.64 avg. 32.88% | Avg: -$0.86 Low: -$0.97 High: -$0.78 avg. 76.25% | Avg: $3.17 Low: $2.89 High: $3.56 avg. 468.50% |
Operating Expenses
% change YoY
| $717.13M N/A | $983.92M 37.20% | $958.24M -2.60% | Avg: $536.12M Low: $486.82M High: $584.65M avg. -44.05% | Avg: $735.09M Low: $684.56M High: $804.11M avg. 37.11% | Avg: $1.01B Low: $942.93M High: $1.10B avg. 37.74% | Avg: $1.55B Low: $1.44B High: $1.69B avg. 53.36% |
FAQ
What is Ultragenyx Pharmaceutical stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 150.07% in 2025-2028.
We have gathered data from 16 analysts. Their low estimate is -495.68M, average is -491.86M and high is -285.35M.
What is Ultragenyx Pharmaceutical stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 42.63% in 2025-2028.
We have gathered data from 15 analysts. Their low revenue estimate is $561.20M, average is $618.04M and high is $673.98M.
What is Ultragenyx Pharmaceutical stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 153.03% in 2025-2028.
We have gathered data from 16 analysts. Their low earnings per share estimate is -$6.74, average is -$5.4 and high is $-3.88.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Ultragenyx Pharmaceutical stock. The most successful analyst is Ed Arce.